However, its off-target actions include the inhibition of PLCG2 by the downregulation of Lyn and Syk, which might be the reason for its good activity against CLL with BTK/PLCG2 mutations [18,44]. This evidence concerns the gene PLCG2 and B-cell chronic lymphocytic leukemia.